ARCHIVES

BMS Execs Knew Of Flaws In ImClone Plan For C225 Prior To $2-Billion Licensing Deal

This article is from The Cancer Letter archive.

Vol. 28 No. 25 | June 21, 2002

Download PDF Visit The Full Archive

Related Articles

NCI’s Frei & Freireich era Lauded As Researchers Receive First NIH Distinguished Alumni Award

September 14, 1990

Funding Opportunities

December 6, 2002

NCI Getting a Lot For a Little Money It Spends Overseas, International Program Director Says

June 17, 1977

Grant, contract Awards Held Up By Impasse On Appropriations

October 14, 1977

BMS Demands Resignation Of Two ImClone Executives

February 8, 2002

FDA Throws Up IND Roadblock, Then Refuses To Answer Investigator’s Letters About It

February 6, 1976